Jacobs Levy Equity Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Jacobs Levy Equity Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.95M	Sell	116,553 -26,163	-18%	-$576K	0.01%	522
2026 Q1	$3.18M	Sell	142,716 -228,331	-62%	-$5.46M	0.01%	504
2025 Q4	$9.91M	Sell	371,047 -371,031	-50%	-$8.87M	0.04%	305
2025 Q3	$15.8M	Sell	742,078 -19,106	-3%	-$452K	0.06%	230
2025 Q2	$16.4M	Sell	761,184 -1,216,248	-62%	-$22.6M	0.06%	236
2025 Q1	$32.8M	Buy	1,977,432 +838,728	+74%	+$15.2M	0.13%	168
2024 Q4	$20.9M	Sell	1,138,704 -72,610	-6%	-$1.17M	0.07%	216
2024 Q3	$18.6M	Sell	1,211,314 -143,688	-11%	-$2.4M	0.07%	245
2024 Q2	$22M	Buy	+1,355,002	New	+$21.9M	0.09%	203
2024 Q1	–	Sell	-105,396	Closed	-$3.3M	–	930
2023 Q4	$3.3M	Sell	105,396 -1,319,007	-93%	-$31.5M	0.02%	511
2023 Q3	$29.7M	Sell	1,424,403 -411,615	-22%	-$11.2M	0.18%	134
2023 Q2	$44M	Sell	1,836,018 -46,335	-2%	-$1.03M	0.25%	99
2023 Q1	$35.4M	Buy	1,882,353 +243,170	+15%	+$4.63M	0.22%	122
2022 Q4	$26.1M	Buy	1,639,183 +552,681	+51%	+$8.64M	0.18%	156
2022 Q3	$17.8M	Buy	+1,086,502	New	+$17.6M	0.14%	185
2022 Q2	–	Sell	-589,726	Closed	-$14.3M	–	985
2022 Q1	$14.3M	Buy	589,726 +48,664	+9%	+$1.18M	0.1%	237
2021 Q4	$12.6M	Buy	541,062 +30,834	+6%	+$620K	0.08%	263
2021 Q3	$8.47M	Buy	+510,228	New	+$9.84M	0.06%	333
2021 Q2	–	Sell	-18,845	Closed	-$486K	–	1018
2021 Q1	$486K	Buy	+18,845	New	+$830K	﹤0.01%	863

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jacobs Levy Equity Management's ACAD Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Acadia Pharmaceuticals (ACAD) stake by 18% in Q2 2026, selling an estimated $576K and leaving 116,553 shares worth $2.95M. The position accounts for 0.01% of the portfolio, ranked #522.

Jacobs Levy Equity Management first reported a position in ACAD in Q1 2021 and has held it in 19 quarters since. The position peaked at $44M in Q2 2023. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Jacobs Levy Equity Management held 116,553 shares of Acadia Pharmaceuticals worth $2.95M as of Q2 2026.
Jacobs Levy Equity Management sold 26,163 Acadia Pharmaceuticals shares in Q2 2026, an estimated $576K.
Acadia Pharmaceuticals made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #522 holding.
Jacobs Levy Equity Management first reported a position in Acadia Pharmaceuticals in Q1 2021 and has held it in 19 quarters since.
Jacobs Levy Equity Management's Acadia Pharmaceuticals position peaked at $44M in Q2 2023.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.